Tanespimycin (17-AAG)

Catalog No.S1141 Synonyms: CP127374,NSC-330507, KOS 953

Molecular Weight(MW): 585.69

Tanespimycin (17-AAG) is a potent HSP90 inhibitor with IC50 of 5 nM in a cell-free assay, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.

Cited by 35 Publications

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Oxid Med Cell Longev, 2019, 2019:2050183

PubMed: 31178953 ( click the link to review the publication )

Int J Biol Sci, 2019, 15(2):312-324

PubMed: 30745823 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2019, 371:63-73

PubMed: 30953615 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):102

PubMed: 30678647 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 47(6):2199-2215

PubMed: 29975948 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(5):1051-1060

PubMed: 29440291 ( click the link to review the publication )

Mycoses, 2018, 61(11):853-856

PubMed: 29998564 ( click the link to review the publication )

ACS Photonics, 2017, 5(2):487-494

PubMed: 29805987 ( click the link to review the publication )

Br J Pharmacol, 2017, 174(5):409-423

PubMed: 28052321 ( click the link to review the publication )

Cell Mol Life Sci, 2017, 74(3):543-554

PubMed: 27592300 ( click the link to review the publication )

Am J Transl Res, 2017, 9(11):4945-4953

PubMed: 29218092 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:2219-2226

PubMed: 28458565 ( click the link to review the publication )

Cell, 2017, 170(5):845-859

PubMed: 28823557 ( click the link to review the publication )

Cancer Res, 2016, 76(4):965-73

PubMed: 26676744 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Medicinal Chemistry Research, 2016, 10.1007/s00044-016-1553-7

PubMed: ( click the link to review the publication )

Oncotarget, 2015, 51: S659-S660

PubMed: ( click the link to review the publication )

Mol Cancer, 2014, 15:30

PubMed: 24927996 ( click the link to review the publication )

ACS Chem Biol, 2014, 9(10):2237-41

PubMed: 25140805 ( click the link to review the publication )

Exp Gerontol, 2014, 52:55-69

PubMed: 24486130 ( click the link to review the publication )

Insect Mol Biol, 2014, 23(6):720-32

PubMed: 25060629 ( click the link to review the publication )

Julius Maximilians Universit, 2014, Kumari G

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(12):4269-82

PubMed: 24962213 ( click the link to review the publication )
Mol Cell, 2013, 50(3):368-78

PubMed: 23583076 ( click the link to review the publication )

Biochim Biophys Acta, 2013, 1830(11):5184-92

PubMed: 23850472 ( click the link to review the publication )

Mol Cell Biol, 2013, 33(12):2375-87

PubMed: 23572559 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2013, 10.1165/rcmb.2013-0214OC

PubMed: 24303801 ( click the link to review the publication )

J Exp Med, 2012, 209(2):259-73

PubMed: 22271575 ( click the link to review the publication )

Biochim Biophys Acta, 2012, 1823(4):911-9

PubMed: 22306003 ( click the link to review the publication )

J Biol Chem, 2012, 287(53):44109-20

PubMed: 23144451 ( click the link to review the publication )

Eukaryot Cell, 2012, 11(11):1324-32

PubMed: 22822234 ( click the link to review the publication )

Age (Dordr), 2012, 35(3):549-62

PubMed: 22252435 ( click the link to review the publication )

P Natl Acad Sci USA, 2011, 108(18):7535-40

PubMed: 21502504 ( click the link to review the publication )

J Nat Prod, 2011, 74(6):1491-9

PubMed: 21553813 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Description

Features

Displays very low toxicity toward normal cells.

Targets

HSP90 ^[1]
(Cell-free assay)

5 nM

In vitro

17-AAG, an analog of geldanamycin, exhibits greater than 100 times higher binding affinity for Hsp90 derived from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells with IC50 values of 5-6 nM. ^[1] 17-AAG causes the degradation of HER2, HER3, Akt, and both mutant and wild-type androgen receptor (AR), leading to the RB-dependent G1 growth arrest of prostate cancer cells such as LNCaP, LAPC-4, DU-145, and PC-3 with IC50 values of 25-45 nM. ^[2] In addition to inducing apoptosis of Ba/F3 cells transformed with wild-type BCR-ABL with an IC50 of 5.2 μM, 17-AAG has the ability to induce apoptosis of cells transformed with imatinib mesylate-resistant T315I and E255K BCR-ABL mutants with IC50 values of 2.3 μM and 1.0 μM, respectively, by inducing the degradation of both wild-type BCR-ABL protein and mutants. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
A549	NE\2NFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIS0eGhKSzVyPUCuNFAxOzB\|IN88US=>	NV\tbmVkW0GQR1XS
IST-MEL1	NWjOR5FbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jicGlEPTB;MD6wNFA1ODdizszN	MoPMV2FPT0WU
NCI-SNU-1	M1jrNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3\pPGlEPTB;MD6wNFIxPyEQvF2=	NEDaNFlUSU6JRWK=
FADU	MmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NITveWNKSzVyPUCuNFAzODlizszN	NYPWSo9SW0GQR1XS
C32	NFHhZmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTBwMECzNFQh\|ryP	NVPmeYdzW0GQR1XS
D-566MG	M1u0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3zoNWlEPTB;MD6wNFM6KM7:TR?=	MXHTRW5ITVJ?
LXF-289	MnTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHu5bIdKSzVyPUCuNFA1OTlizszN	MmOxV2FPT0WU
HGC-27	NWXkWXZGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoTuTWM2OD1yLkCwOVEh\|ryP	NIjk[mNUSU6JRWK=
RPMI-7951	NGf0Um1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTBwMEC3NVch\|ryP	MXzTRW5ITVJ?
HSC-3	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnkTWM2OD1yLkCwPVI6KM7:TR?=	M{m4fnNCVkeHUh?=
MIA-PaCa-2	NWXTXGNZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTBwMEGwNFkh\|ryP	M1GwdXNCVkeHUh?=
KS-1	M{C0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3rVOmlEPTB;MD6wNVM2PSEQvF2=	NF30VWlUSU6JRWK=
CAL-51	M4LEWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXrJR\|UxRTBwMEG0NFUh\|ryP	NF\CcIxUSU6JRWK=
MDA-MB-361	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTBwMEG0PVUh\|ryP	Mn6zV2FPT0WU
TI-73	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXHyfoNCUUN3ME2wMlAyPzl4IN88US=>	MkDqV2FPT0WU
AGS	NUHzZVB5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2HkR2lEPTB;MD6wNVk{QCEQvF2=	MXTTRW5ITVJ?
NCI-H460	NXLXZXNKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnXETWM2OD1yLkCxPVc1KM7:TR?=	MnvNV2FPT0WU
A204	NGLI[HFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3q5OWlEPTB;MD6wNlI1QSEQvF2=	MkixV2FPT0WU
CHL-1	NXjtZWQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFrnO21KSzVyPUCuNFIzPTFizszN	NGLLZlVUSU6JRWK=
DU-4475	NUntOHg4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;aNJA1UUN3ME2wMlAzOjZzIN88US=>	MYPTRW5ITVJ?
CGTH-W-1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIe3W2ZKSzVyPUCuNFI{PDlizszN	NIPudZRUSU6JRWK=
HCC2218	NG[xdoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTBwMEK0PVQh\|ryP	MWDTRW5ITVJ?
A2780	NXzPb4tiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33l[GlEPTB;MD6wNlU{OSEQvF2=	NHnNfHhUSU6JRWK=
NCI-H720	NYrxToh7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWrzSWQzUUN3ME2wMlAzPTR4IN88US=>	NXHJ[29xW0GQR1XS
NCI-N87	NFjtRoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkjBTWM2OD1yLkCyOVk{KM7:TR?=	MXjTRW5ITVJ?
CHP-212	NHraNHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\ocWNKSzVyPUCuNFI3OjhizszN	NW\hZ2trW0GQR1XS
NCI-H23	NFzPSVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTBwMEK2OlUh\|ryP	MlTDV2FPT0WU
D-263MG	MlLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHfVOZlKSzVyPUCuNFI4QDZizszN	NYX0[GxCW0GQR1XS
ME-180	NXzyUXc6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFe3cVBKSzVyPUCuNFI5QTFizszN	NFvVVHVUSU6JRWK=
SW982	M3HYS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTWTWM2OD1yLkCyPVk6KM7:TR?=	MU\TRW5ITVJ?
OE19	NY\0ZlVvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlnTTWM2OD1yLkCzNFc4KM7:TR?=	Mom2V2FPT0WU
SK-LU-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXjJR\|UxRTBwMEOwPFIh\|ryP	M{K4TnNCVkeHUh?=
H4	NFrDOJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlvLTWM2OD1yLkCzNFkh\|ryP	MmHSV2FPT0WU
HT-144	M37BWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4DTS2lEPTB;MD6wN\|A6OyEQvF2=	Mn3vV2FPT0WU
SK-UT-1	M{D6OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4GwWmlEPTB;MD6wN\|E4QCEQvF2=	NYLH[JVHW0GQR1XS
D-336MG	MnLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV7JR\|UxRTBwMEOzNFkh\|ryP	Ml7yV2FPT0WU
MDA-MB-175-VII	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2fDXWlEPTB;MD6wN\|M2PCEQvF2=	MnP0V2FPT0WU
GAMG	MmXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTBwMEO0N\|Uh\|ryP	NWjvdXJ2W0GQR1XS
CP50-MEL-B	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEfscZBKSzVyPUCuNFM1PSEQvF2=	M{[y[HNCVkeHUh?=
OVCAR-5	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYnoSlBUUUN3ME2wMlA{PDhizszN	NIjtc4FUSU6JRWK=
SK-MES-1	NHTqRZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MofVTWM2OD1yLkCzOlA3KM7:TR?=	NXTNXoJoW0GQR1XS
VM-CUB-1	MmPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHPL[FhKSzVyPUCuNFM3PTdizszN	NYTybHQxW0GQR1XS
WM-115	NEnkSXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MojNTWM2OD1yLkCzO\|YzKM7:TR?=	MWXTRW5ITVJ?
DSH1	NGrV[JJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV7BbINDUUN3ME2wMlA{QDB5IN88US=>	NYnzSZg5W0GQR1XS
Becker	M3\Hfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTBwMEO4PFUh\|ryP	NEPBR3JUSU6JRWK=
SW962	Ml3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmP3TWM2OD1yLkCzPVQ2KM7:TR?=	M12yZ3NCVkeHUh?=
TYK-nu	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\EZlZKSzVyPUCuNFM6QDVizszN	MnT1V2FPT0WU
HO-1-N-1	NH\FcINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4DKeGlEPTB;MD6wOFAzOSEQvF2=	MVTTRW5ITVJ?
T98G	NGTzemhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTBwMESxNFMh\|ryP	NVr6VopwW0GQR1XS
ACN	M4nsdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV24TFkyUUN3ME2wMlA1OTZ{IN88US=>	MlfKV2FPT0WU
SW780	NXLmXZM1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{DxUmlEPTB;MD6wOFIxOyEQvF2=	MUnTRW5ITVJ?
Detroit562	NHfvVWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTBwMESyN\|kh\|ryP	M4HHUnNCVkeHUh?=
BB49-HNC	M1HTc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Moi1TWM2OD1yLkC0NlQ{KM7:TR?=	NX31dpBXW0GQR1XS
HN	M2Hmemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWXMbGNTUUN3ME2wMlA1Ojd{IN88US=>	MkDqV2FPT0WU
H9	MmDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVfhZVliUUN3ME2wMlA1OzdzIN88US=>	MWfTRW5ITVJ?
VA-ES-BJ	Mo[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDsemJIUUN3ME2wMlA1PDR5IN88US=>	NETLVIZUSU6JRWK=
MEL-JUSO	NF3mT5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXybFdKSzVyPUCuNFQ1PzVizszN	M2\zTHNCVkeHUh?=
BT-474	M3zCWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGrDdpBKSzVyPUCuNFQ2KM7:TR?=	M{jLc3NCVkeHUh?=
CaR-1	NHX6XFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGOxWnVKSzVyPUCuNFQ2PDlizszN	MWLTRW5ITVJ?
PSN1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVzN[\|BQUUN3ME2wMlA1PjB\|IN88US=>	NW[2UpFJW0GQR1XS
KYSE-510	NGjPS5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGTkVZBKSzVyPUCuNFQ3PDlizszN	NWDiO2F{W0GQR1XS
KP-4	NV;TNIVwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1nKXWlEPTB;MD6wOFc2OyEQvF2=	Mmi5V2FPT0WU
KYSE-410	NHHDc2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnr1TWM2OD1yLkC0O\|czKM7:TR?=	M4XsdHNCVkeHUh?=
G-402	Mlr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF7jdFZKSzVyPUCuNFQ4QDlizszN	NFjabWlUSU6JRWK=
DOK	NY\RO29{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTBwMES5NFIh\|ryP	M2C1R3NCVkeHUh?=
COR-L88	NUTXU\|MyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml7xTWM2OD1yLkC0PVEzKM7:TR?=	NVi2Z21jW0GQR1XS
SKG-IIIa	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\STWM2OD1yLkC0PVg3KM7:TR?=	NIH4eFFUSU6JRWK=
AN3-CA	NVPIO5ZuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTBwMEWg{txO	MmL1V2FPT0WU
SW48	NEPUXVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWHzc21lUUN3ME2wMlA2ODN7IN88US=>	MmHXV2FPT0WU
YKG-1	MlvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTBwMEWwO\|Eh\|ryP	MlrOV2FPT0WU
KYSE-150	NHrz[IpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn:3TWM2OD1yLkC1NlM2KM7:TR?=	MUDTRW5ITVJ?
HuO-3N1	NXO4WIVwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLCcG9KSzVyPUCuNFUzOzdizszN	NF33[2JUSU6JRWK=
LB1047-RCC	NUXuUmtwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVzJR\|UxRTBwMEWyPVYh\|ryP	MX3TRW5ITVJ?
NCI-H2030	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTBwMEW0NVQh\|ryP	Ml3JV2FPT0WU
YH-13	NEewXJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTBwMEW3NlIh\|ryP	NV7CRXNLW0GQR1XS
5637	M1\D[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkL5TWM2OD1yLkC1O\|Qh\|ryP	NFqxR4FUSU6JRWK=
LOXIMVI	M2[zWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLpTWM2OD1yLkC1PFczKM7:TR?=	NF3HSJdUSU6JRWK=
GT3TKB	NGHUTVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTBwMEW5OFIh\|ryP	MXfTRW5ITVJ?
TCCSUP	M{PrWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXn1UGtDUUN3ME2wMlA2QTZ2IN88US=>	NF7KV3VUSU6JRWK=
EPLC-272H	NIHlPVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGi3dWtKSzVyPUCuNFYzODVizszN	MYXTRW5ITVJ?
LU-99A	M1noNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWTJR\|UxRTBwME[yN\|ch\|ryP	MnHhV2FPT0WU
NCI-H1755	M320VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml\sTWM2OD1yLkC2N\|QyKM7:TR?=	M3vLXXNCVkeHUh?=
KM12	MmTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTBwME[zOFgh\|ryP	M2ix[nNCVkeHUh?=
SF295	MmPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlmzTWM2OD1yLkC2OFUzKM7:TR?=	NWTz[ZNxW0GQR1XS
MZ2-MEL	MlPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXuV5FKSzVyPUCuNFY2PTNizszN	NFrMclBUSU6JRWK=
HEC-1	MlLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlv0TWM2OD1yLkC2OVg5KM7:TR?=	MmruV2FPT0WU
SW684	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV62fnlLUUN3ME2wMlA3PTlzIN88US=>	M3PVNHNCVkeHUh?=
SF539	M3TCemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\wTWM2OD1yLkC2OlgyKM7:TR?=	MWXTRW5ITVJ?
GMS-10	NV65S3hjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml7PTWM2OD1yLkC2Olk6KM7:TR?=	NHPtbmVUSU6JRWK=
MV-4-11	NGryfnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVLBSYFQUUN3ME2wMlA3QDB\|IN88US=>	NYfxOZR5W0GQR1XS
HT-29	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGTiUoJKSzVyPUCuNFY6OTlizszN	M2DzTXNCVkeHUh?=
23132-87	M3nQWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXzkfG1LUUN3ME2wMlA3QTVizszN	NX24[3pIW0GQR1XS
SW620	NY\oV4FlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXOeo1KSzVyPUCuNFcxOjZizszN	NXWy[lFqW0GQR1XS
HCC1806	Mmj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnq1TWM2OD1yLkC3NVMyKM7:TR?=	NI\mSJRUSU6JRWK=
Hs-578-T	Mm\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDXTWM2OD1yLkC3NlA5KM7:TR?=	NGDiTYRUSU6JRWK=
A2058	Mn;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3XXSGlEPTB;MD6wO\|IzQCEQvF2=	NHviOoVUSU6JRWK=
MEL-HO	M1zrS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7EbYtKSzVyPUCuNFczPTVizszN	M{n2S3NCVkeHUh?=
HCC2998	MoDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFjHRmhKSzVyPUCuNFc{PDdizszN	NU\0T412W0GQR1XS
HuO9	MonTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEP5W\|BKSzVyPUCuNFc2QDlizszN	NX7XR3NTW0GQR1XS
CAL-39	NYTzPI51T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1rtWmlEPTB;MD6wO\|c3PiEQvF2=	M3\5TXNCVkeHUh?=
M14	M3vPdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLLNGZKSzVyPUCuNFc6OTNizszN	NIHh[2ZUSU6JRWK=
BFTC-909	NYC2XVJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3HTTWlEPTB;MD6wO\|k3QSEQvF2=	MVPTRW5ITVJ?
TE-11	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYS4W3hlUUN3ME2wMlA4QTl4IN88US=>	MnfzV2FPT0WU
TGBC1TKB	NVSwbGF5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{fNbGlEPTB;MD6wPFA1OyEQvF2=	NEiyZZlUSU6JRWK=
L-363	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFzsUWVKSzVyPUCuNFgzODZizszN	NXu5U5B6W0GQR1XS
A431	M4jU[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4LsWGlEPTB;MD6wPFIyKM7:TR?=	MVjTRW5ITVJ?
MKN45	MkLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGLxWVdKSzVyPUCuNFgzOTlizszN	MUHTRW5ITVJ?
HT-1080	NG\oVHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mk\1TWM2OD1yLkC4OFM6KM7:TR?=	M{HR[XNCVkeHUh?=
OVCAR-8	M3PVeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTBwMEi2NlIh\|ryP	MnT2V2FPT0WU
LCLC-97TM1	NGDIcoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXvNVYhZUUN3ME2wMlA5PzJ6IN88US=>	NX3oS4JIW0GQR1XS
M059J	NF\yRmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX\JR\|UxRTBwMEmwNlch\|ryP	MX3TRW5ITVJ?
SK-MEL-2	NIrUWZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zPVmlEPTB;MD6wPVA3KM7:TR?=	M37GeXNCVkeHUh?=
TE-1	NEHmTGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlfzTWM2OD1yLkC5NlA1KM7:TR?=	M2PhSHNCVkeHUh?=
KYSE-180	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTBwMEmyOlIh\|ryP	MofLV2FPT0WU
D-247MG	M4HrUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYDJR\|UxRTBwMEm0OVUh\|ryP	NYfHcVFxW0GQR1XS
8-MG-BA	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYD2R4pqUUN3ME2wMlA6PDd{IN88US=>	NGG0RmFUSU6JRWK=
NCI-H1792	NUTWbllCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlmzTWM2OD1yLkC5OlE5KM7:TR?=	Mk[yV2FPT0WU
MCF7	Mnr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG\0[5JKSzVyPUCuNFk3PzdizszN	NWPjPJpoW0GQR1XS
NCI-H2122	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfkTWM2OD1yLkC5O\|Q2KM7:TR?=	MmHWV2FPT0WU
EFO-27	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTBwMEm5PVch\|ryP	Mn76V2FPT0WU
LB2241-RCC	NICyTFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInYeZJKSzVyPUCuNVAxPTRizszN	NYPLZmw4W0GQR1XS
SN12C	NH7WO49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnv4TWM2OD1yLkGwNVA4KM7:TR?=	MW\TRW5ITVJ?
A498	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUT0SmJiUUN3ME2wMlExOThizszN	MW\TRW5ITVJ?
PANC-03-27	NEjoZ5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTqTWM2OD1yLkGwNlg3KM7:TR?=	MXzTRW5ITVJ?
NCI-H1581	MkDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3rQc2lEPTB;MD6xNFI6KM7:TR?=	Ml:5V2FPT0WU
U-87-MG	M2\ObWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTBwMUCzNFch\|ryP	MnvvV2FPT0WU
G-401	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX20TJZuUUN3ME2wMlExOzV\|IN88US=>	NGD5RpNUSU6JRWK=
SiHa	NVfwOoV4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTBwMUC0PFYh\|ryP	MWHTRW5ITVJ?
U251	NWjWOmlKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml7VTWM2OD1yLkGwOVI2KM7:TR?=	NFTTcmZUSU6JRWK=
MMAC-SF	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWHkcXZlUUN3ME2wMlExPTNzIN88US=>	NFP4SHJUSU6JRWK=
BB65-RCC	NWnI[pFtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3y5O2lEPTB;MD6xNFU2PCEQvF2=	NIHlPXlUSU6JRWK=
NKM-1	M3XmSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1uzPGlEPTB;MD6xNFY3PiEQvF2=	MlniV2FPT0WU
HD-MY-Z	NUfWdG5xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWTJR\|UxRTBwMUC4O\|Mh\|ryP	MnW5V2FPT0WU
TGBC11TKB	M3XwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3r6[GlEPTB;MD6xNFkxOyEQvF2=	NITQSoZUSU6JRWK=
COLO-679	M2\jXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mli1TWM2OD1yLkGxNlEyKM7:TR?=	NVnTcZlzW0GQR1XS
TE-8	M17VSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWHwR4x{UUN3ME2wMlEyOjZ2IN88US=>	M{XTR3NCVkeHUh?=
SK-MEL-28	NY\j[nVyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFzhTXdKSzVyPUCuNVE{OjFizszN	NFr1NVhUSU6JRWK=
SH-4	NXHTUIR7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M121eGlEPTB;MD6xNVM2PiEQvF2=	NID4dG9USU6JRWK=
KALS-1	NX;C[HR[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXzpO\|BwUUN3ME2wMlEyOzl\|IN88US=>	MX7TRW5ITVJ?
RKO	NWT6SXJST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUTrVGIyUUN3ME2wMlEyPzZ2IN88US=>	M3HLSXNCVkeHUh?=
OMC-1	NEPSeIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlfoTWM2OD1yLkGxO\|k4KM7:TR?=	NVfEb2lqW0GQR1XS
BT-549	MlK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3r0cmlEPTB;MD6xNVc6QSEQvF2=	MWnTRW5ITVJ?
NCI-H28	MmHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HVTGlEPTB;MD6xNVgyPyEQvF2=	MnXwV2FPT0WU
RXF393	MlPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\rUHJjUUN3ME2wMlEyQTh{IN88US=>	NEjsbHZUSU6JRWK=
COLO-829	NGi4OplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXzbIhKSzVyPUCuNVIxODVizszN	NH3ZUo9USU6JRWK=
HMV-II	NHrvRYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DlfmlEPTB;MD6xNlAzKM7:TR?=	M1jhRnNCVkeHUh?=
SW1990	NIDBNXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYW0U41IUUN3ME2wMlEzOTV5IN88US=>	NID3S2JUSU6JRWK=
NCI-H1437	M3TrN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;6TJFKSzVyPUCuNVIyPTdizszN	MXjTRW5ITVJ?
SNB75	Mk\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoL5TWM2OD1yLkGyNVY6KM7:TR?=	M2XxVXNCVkeHUh?=
EW-3	M4PZNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWfBWFdxUUN3ME2wMlEzPjZzIN88US=>	MlO3V2FPT0WU
SAS	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGTCdZNKSzVyPUCuNVI3QSEQvF2=	NFq5UGZUSU6JRWK=
NCI-H1666	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkjLTWM2OD1yLkGyO\|c1KM7:TR?=	NXLm[FVSW0GQR1XS
A375	Ml7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTBwMUK3O\|gh\|ryP	NEjFZmZUSU6JRWK=
CAMA-1	NF7ucWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfXTWM2OD1yLkGyPVI1KM7:TR?=	NWOyfXRPW0GQR1XS
HuP-T4	Ml;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLxTWM2OD1yLkGyPVQ{KM7:TR?=	NV7GTlR[W0GQR1XS
NCI-H292	MlLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fPNGlEPTB;MD6xN\|EyKM7:TR?=	MYTTRW5ITVJ?
PC-14	NWXIc\|BmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGDQc2ZKSzVyPUCuNVMzOTFizszN	MX7TRW5ITVJ?
BPH-1	M3r1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3S5NGlEPTB;MD6xN\|QyKM7:TR?=	MkXQV2FPT0WU
GAK	MkHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnLYTWM2OD1yLkGzOVY4KM7:TR?=	NYDlZotwW0GQR1XS
VMRC-RCZ	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkPtTWM2OD1yLkGzO\|YzKM7:TR?=	NH74NIJUSU6JRWK=
SK-MEL-24	MkizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTBwMUO4O{DPxE1?	NYPveZJjW0GQR1XS
LB831-BLC	M2fMeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7STZlKSzVyPUCuNVM5QDNizszN	MYjTRW5ITVJ?
NCI-H2452	NUDnb3ZNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFPYXHdKSzVyPUCuNVM6PTZizszN	MnPPV2FPT0WU
RT-112	NHruNGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn7UTWM2OD1yLkG0NFM2KM7:TR?=	M4HUcHNCVkeHUh?=
GP5d	MlrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PrSWlEPTB;MD6xOFExPCEQvF2=	NFXGenRUSU6JRWK=
LC-2-ad	M2G2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{jRd2lEPTB;MD6xOFEzOSEQvF2=	MVPTRW5ITVJ?
MPP-89	NUPUWYsyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NI\2cXdKSzVyPUCuNVQyOjVizszN	Mn3rV2FPT0WU
NUGC-3	NWDke3JDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;hcmlEPTB;MD6xOFQ4QCEQvF2=	NV\OdXhLW0GQR1XS
GI-1	Mo\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVnQW4hpUUN3ME2wMlE1PTV6IN88US=>	MoHDV2FPT0WU
HCC1419	NHLOTItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NELPTlJKSzVyPUCuNVQ2PzZizszN	MWDTRW5ITVJ?
SW1573	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH20R5pKSzVyPUCuNVQ4PThizszN	NV7YfW1ZW0GQR1XS
NCI-H2347	NHXPXWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEDFTWRKSzVyPUCuNVQ5OzlizszN	NX7aWWhlW0GQR1XS
Mewo	NHfyeo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2r4ZWlEPTB;MD6xOFg5QSEQvF2=	NX;q[Wl5W0GQR1XS
639-V	MlXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2H6O2lEPTB;MD6xOVAyOyEQvF2=	NGTBVXNUSU6JRWK=
AsPC-1	M1fxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTBwMUWyNlUh\|ryP	MWLTRW5ITVJ?
NCI-H1648	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGCwU\|VKSzVyPUCuNVUzOzJizszN	MlPBV2FPT0WU
786-0	MlPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTBwMUWzPFEh\|ryP	MWrTRW5ITVJ?
ETK-1	Ml;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTBwMUW5JO69VQ>?	MlGxV2FPT0WU
BxPC-3	MofKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4fuV2lEPTB;MD6xOVk3PiEQvF2=	Moj5V2FPT0WU
CAL-62	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWLJR\|UxRTBwMU[xOlkh\|ryP	MXjTRW5ITVJ?
HCC1937	MnXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo\BTWM2OD1yLkG2Nlc2KM7:TR?=	MWHTRW5ITVJ?
NCI-H1299	M3;5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV\vS2lIUUN3ME2wMlE3Ojh3IN88US=>	NVHmNY5WW0GQR1XS
SW1088	Mm\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnuXmxSUUN3ME2wMlE3PDF\|IN88US=>	NYezdGN[W0GQR1XS
FTC-133	NGX3W\|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{jzSGlEPTB;MD6xOlU1KM7:TR?=	M4PuRXNCVkeHUh?=
OC-314	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M17oPGlEPTB;MD6xOlY6KM7:TR?=	MWDTRW5ITVJ?
SCC-9	M4ThfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTBwMU[3NVYh\|ryP	NWPjTlA5W0GQR1XS
HT-1376	M{m2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTBwMU[5N\|Yh\|ryP	NHPCO3ZUSU6JRWK=
U-2-OS	NIfVRplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmnRTWM2OD1yLkG3NVc{KM7:TR?=	MlK5V2FPT0WU
COLO-824	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVvJR\|UxRTBwMUeyPVQh\|ryP	NIm5SopUSU6JRWK=
BB30-HNC	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTBwMUezN{DPxE1?	MoLYV2FPT0WU
NCI-H2087	NIXJfmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjFT4ptUUN3ME2wMlE4OzZ6IN88US=>	NVfRNJRvW0GQR1XS
NCI-H2170	M{TEdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3W3eGlEPTB;MD6xO\|U{PiEQvF2=	M1;JPHNCVkeHUh?=
SK-OV-3	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF3XOVJKSzVyPUCuNVc2PzFizszN	Mn\iV2FPT0WU
MZ7-mel	MmXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFS0N3hKSzVyPUCuNVc3PDlizszN	NEjRdFFUSU6JRWK=
NCI-H650	NXzKPVVqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jUSmlEPTB;MD6xO\|Y5OiEQvF2=	MYTTRW5ITVJ?
KOSC-2	M3vpS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTtTWM2OD1yLkG3O\|M1KM7:TR?=	NW\5dZp6W0GQR1XS
SCC-4	NYrwWodUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4nrO2lEPTB;MD6xO\|c4PyEQvF2=	NULKRlI2W0GQR1XS
MDA-MB-157	NWjSfmsyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTBwMUiwPFIh\|ryP	M3nOVnNCVkeHUh?=
KYSE-520	MlL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlLoTWM2OD1yLkG4NkDPxE1?	M2S5fnNCVkeHUh?=
LK-2	NFnxemdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTBwMUizNFMh\|ryP	NXHtdVZyW0GQR1XS
KNS-81-FD	NXnzPHdrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYS0O3l2UUN3ME2wMlE5Ozl2IN88US=>	MXTTRW5ITVJ?
IGROV-1	NYn5blVHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWK0bnZqUUN3ME2wMlE5PDR\|IN88US=>	NXLlN4tsW0GQR1XS
DEL	NYX5S41mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2jERmlEPTB;MD6xPFQ2KM7:TR?=	NUnOVIdKW0GQR1XS
NCI-H1395	MmDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFrTd3VKSzVyPUCuNVg3QDJizszN	MnG3V2FPT0WU
JEG-3	MoK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV[2Z\|ltUUN3ME2wMlE5PzB3IN88US=>	M4i2WnNCVkeHUh?=
BCPAP	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGq1[o9KSzVyPUCuNVg5PzJizszN	MmWyV2FPT0WU
CAL-27	MkfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWDJR\|UxRTBwMUmwNlIh\|ryP	M1;COXNCVkeHUh?=
RD	NVPjUHZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLxTWM2OD1yLkG5NVE{KM7:TR?=	NX[zVpJDW0GQR1XS
RVH-421	NGCycZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{XKOGlEPTB;MD6xPVEyPiEQvF2=	M4f0ZXNCVkeHUh?=
Capan-2	NGmzfJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnv1TWM2OD1yLkG5NlU3KM7:TR?=	M1PQT3NCVkeHUh?=
COLO-680N	M3e4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTBwMUmzOlQh\|ryP	MnTZV2FPT0WU
NCI-H1650	NHfh[nFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVP5epR[UUN3ME2wMlIxODV5IN88US=>	NHnIfIVUSU6JRWK=
SBC-5	M3LxNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4j4dGlEPTB;MD6yNFEyQCEQvF2=	MWjTRW5ITVJ?
U031	NFHZNXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHPrUGxKSzVyPUCuNlA2PDdizszN	NEO3dopUSU6JRWK=
S-117	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml7RTWM2OD1yLkKwOVY1KM7:TR?=	NUPiO3lYW0GQR1XS
DoTc2-4510	NF;PW5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\ScnFKSzVyPUCuNlA4PjlizszN	MmTsV2FPT0WU
AM-38	M{ftdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnXYTWM2OD1yLkKwPFQ5KM7:TR?=	NULsWmdIW0GQR1XS
A172	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYPuTG51UUN3ME2wMlIyODJ{IN88US=>	M{DsU3NCVkeHUh?=
HPAF-II	M3H4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWLmdVNLUUN3ME2wMlIyOjZ2IN88US=>	M373dXNCVkeHUh?=
769-P	MoT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTBwMkGyPEDPxE1?	MXfTRW5ITVJ?
MFE-280	NGX2[mNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoLtTWM2OD1yLkKxNlk5KM7:TR?=	NXnnenZkW0GQR1XS
TE-9	NGnDblBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTITWM2OD1yLkKxO\|g3KM7:TR?=	MoDCV2FPT0WU
C2BBe1	MlXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIO4eYZKSzVyPUCuNlIyQSEQvF2=	MU\TRW5ITVJ?
EoL-1-cell	M1PWWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;QXplXUUN3ME2wMlIzOjB\|IN88US=>	NYL4S5luW0GQR1XS
G-361	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkPpTWM2OD1yLkKyOlgzKM7:TR?=	MnXPV2FPT0WU
KYSE-270	NF7ofnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRTBwMkOwPFQh\|ryP	M{LrXnNCVkeHUh?=
TK10	MofIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGiwVIJKSzVyPUCuNlMyOTdizszN	Ml;rV2FPT0WU
ML-2	M4HIPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXTbmpDUUN3ME2wMlI{OTF7IN88US=>	NFL6O3hUSU6JRWK=
MHH-ES-1	NWDLN2syT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTBwMkO2PFEh\|ryP	MlT0V2FPT0WU
BHY	NFzIdHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXzNTFR3UUN3ME2wMlI{PjlzIN88US=>	NELxTWtUSU6JRWK=
LS-513	NX:0UXV6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHrWXVNKSzVyPUCuNlM6PjFizszN	M1\pVXNCVkeHUh?=
COLO-678	NUjUSW1LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfCblN4UUN3ME2wMlI1ODR2IN88US=>	NFzyWYRUSU6JRWK=
NCI-H747	NV\BZlgyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLBc5g1UUN3ME2wMlI1OTZ7IN88US=>	MoTxV2FPT0WU
K5	NEjjNY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXnLS\|l6UUN3ME2wMlI1OzhizszN	MVfTRW5ITVJ?
OS-RC-2	NWjaVmNFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlq2TWM2OD1yLkK0OVA6KM7:TR?=	NVPTeYpoW0GQR1XS
KINGS-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV\JR\|UxRTBwMkS1Nlkh\|ryP	MnrEV2FPT0WU
SCC-25	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\MSpFKSzVyPUCuNlQ2PjNizszN	NYrkbIRvW0GQR1XS
CAPAN-1	NHe1NolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHT2VopKSzVyPUCuNlQ4QDNizszN	MXrTRW5ITVJ?
ESS-1	MlXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MomyTWM2OD1yLkK0PFA2KM7:TR?=	M2TrR3NCVkeHUh?=
TE-6	NWnHVIZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3jiUGlEPTB;MD6yOVc2KM7:TR?=	NYLCWVlIW0GQR1XS
LB2518-MEL	NUGwO245T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoHWTWM2OD1yLkK1O\|c4KM7:TR?=	M33OUXNCVkeHUh?=
COLO-800	M2q2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLpTWM2OD1yLkK1PFEzKM7:TR?=	NUn2bpZIW0GQR1XS
LU-134-A	NVfxd4VET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2\SSmlEPTB;MD6yOlE{PiEQvF2=	NIXXd3NUSU6JRWK=
NCI-H1155	NUjFeHQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTBwMk[xOlIh\|ryP	NVPyPJpiW0GQR1XS
MFM-223	NHHwfmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1zycGlEPTB;MD6yOlM3OyEQvF2=	MkTZV2FPT0WU
HTC-C3	NGjvdFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnzoTWM2OD1yLkK2OVA3KM7:TR?=	MUfTRW5ITVJ?
HCT-116	NIjzcYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYTJR\|UxRTBwMk[1PVkh\|ryP	MWnTRW5ITVJ?
Ca-Ski	MkT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHriZ\|lKSzVyPUCuNlY3PzhizszN	MWXTRW5ITVJ?
SBC-1	MorCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPj[3BKSzVyPUCuNlY4PDJizszN	NWezVIlmW0GQR1XS
NB69	NHvaeVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MojlTWM2OD1yLkK3NFg4KM7:TR?=	NUTxOldiW0GQR1XS
J82	NGjzNIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVXJR\|UxRTBwMkeyOlUh\|ryP	M4f1XXNCVkeHUh?=
U-118-MG	NGPxWYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTBwMke1O\|kh\|ryP	NH7CTmZUSU6JRWK=
NCI-H1355	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYH6emNnUUN3ME2wMlI5ODd2IN88US=>	NITWb25USU6JRWK=
NCI-H1048	NYm2VpluT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTBwMki5OVYh\|ryP	MmmyV2FPT0WU
SW954	NV7CXlBtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkewTWM2OD1yLkK5NlI4KM7:TR?=	M4m1XHNCVkeHUh?=
NMC-G1	NIrQVo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml\oTWM2OD1yLkK5Nlc4KM7:TR?=	MYfTRW5ITVJ?
SW1710	NIX1enpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTBwMkm0PVQh\|ryP	MlS1V2FPT0WU
KY821	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTBwMkm4O\|Ih\|ryP	MkfxV2FPT0WU
HCC38	NFi4O29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVvpPZdsUUN3ME2wMlMxODd6IN88US=>	M4HaeHNCVkeHUh?=
NCI-SNU-5	M3K1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDOT\|JKSzVyPUCuN\|A2PCEQvF2=	NX:2[Ho3W0GQR1XS
ES8	NIW5UXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYjJR\|UxRTBwM{C3PFQh\|ryP	NFvVPFlUSU6JRWK=
COLO-792	NYfofm9jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXnvWY41UUN3ME2wMlMyOjVzIN88US=>	NV7xR4hJW0GQR1XS
BFTC-905	NILBSJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkD1TWM2OD1yLkOxOVIyKM7:TR?=	NFXlfo1USU6JRWK=
ChaGo-K-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTBwM{G3NVUh\|ryP	M1vzV3NCVkeHUh?=
Daoy	M4roXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIjpWHVKSzVyPUCuN\|E4OjNizszN	M4TrbHNCVkeHUh?=
SJSA-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoTuTWM2OD1yLkOxPFQ4KM7:TR?=	NHr5XXVUSU6JRWK=
KNS-62	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlnrTWM2OD1yLkOyNFg5KM7:TR?=	MmDHV2FPT0WU
CAKI-1	NGLnTFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn3VTWM2OD1yLkOyNVEyKM7:TR?=	M2PWU3NCVkeHUh?=
UACC-62	Moq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYG3WoZSUUN3ME2wMlMzOjJ5IN88US=>	MnTCV2FPT0WU
HuCCT1	MljkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHzJWGJKSzVyPUCuN\|IzQDNizszN	MkDqV2FPT0WU
CTB-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjxUWNDUUN3ME2wMlMzPzV\|IN88US=>	M1X6RnNCVkeHUh?=
NTERA-S-cl-D1	M2\1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTBwM{K4N\|Yh\|ryP	MU\TRW5ITVJ?
T-24	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnT4TWM2OD1yLkOzNVU6KM7:TR?=	MnOxV2FPT0WU
KYSE-70	M3HPXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIqwNnpKSzVyPUCuN\|MzQDNizszN	MYTTRW5ITVJ?
SW626	NH\pRppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVjzWZE4UUN3ME2wMlM{PTN{IN88US=>	MlTvV2FPT0WU
LB996-RCC	NVXaOZR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTBwM{O2NVkh\|ryP	NGfRVGxUSU6JRWK=
DMS-273	M2PYeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVnXSWhsUUN3ME2wMlM{QTF4IN88US=>	NHrGSnBUSU6JRWK=
SW1783	M1nBWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{\uRWlEPTB;MD6zN\|k6PyEQvF2=	NFjTbHJUSU6JRWK=
KU812	M13Rcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlToTWM2OD1yLkO0NFM5KM7:TR?=	NED4N45USU6JRWK=
HSC-2	M3XHfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXPpPXE2UUN3ME2wMlM1ODV\|IN88US=>	NFv6VohUSU6JRWK=
A3-KAW	M{fScGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTVd5lkUUN3ME2wMlM1OTZ{IN88US=>	MWTTRW5ITVJ?
COLO-684	M1\3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M17OZWlEPTB;MD6zOFUxOSEQvF2=	Mnf2V2FPT0WU
NCI-H2405	MmTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2LWUWlEPTB;MD6zOFY{OSEQvF2=	Mn7yV2FPT0WU
NCI-H2228	NIK4NodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnzNpRKSzVyPUCuN\|U{PTdizszN	MVzTRW5ITVJ?
NB13	M2\0Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTBwM{[4Nlkh\|ryP	MWLTRW5ITVJ?
no-11	MnXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUW3dpBbUUN3ME2wMlM3QTVizszN	M2jzfHNCVkeHUh?=
DK-MG	NFK5fWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGOzNFRKSzVyPUCuN\|cyQDhizszN	NHrJXHJUSU6JRWK=
NBsusSR	MmLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXvJR\|UxRTBwM{eyPFUh\|ryP	Mn3TV2FPT0WU
KP-N-YS	MnHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M13JcWlEPTB;MD6zO\|Q3OyEQvF2=	M3zHRXNCVkeHUh?=
CFPAC-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF65bXlKSzVyPUCuN\|c2OThizszN	M1LGNnNCVkeHUh?=
KARPAS-45	NVK4U2luT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlnZTWM2OD1yLkO3PFYzKM7:TR?=	MnLnV2FPT0WU
NCI-H1793	M{TnO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13FdWlEPTB;MD6zPFUyKM7:TR?=	MlzYV2FPT0WU
HCE-T	Ml\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\uN4dxUUN3ME2wMlM5PjB\|IN88US=>	M4HVUHNCVkeHUh?=
NCI-H520	NID4VnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUGzVoNPUUN3ME2wMlM5PzB\|IN88US=>	MVHTRW5ITVJ?
HCC2157	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWK4UpZDUUN3ME2wMlM5PzhzIN88US=>	MUPTRW5ITVJ?
EW-18	M1HzUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2fiUGlEPTB;MD6zPFk1OSEQvF2=	M4XMeXNCVkeHUh?=
RO82-W-1	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3fhfmlEPTB;MD6zPVY6QSEQvF2=	NUPBb2dDW0GQR1XS
HuP-T3	M4DqeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVnJR\|UxRTBwNECxOFMh\|ryP	M2DQd3NCVkeHUh?=
PANC-10-05	NIfZ[FJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFeyXI9KSzVyPUCuOFEyPyEQvF2=	MoTOV2FPT0WU
NCI-H1703	NVv4d4l1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTBwNEG0OFYh\|ryP	MoLiV2FPT0WU
TE-10	MnnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV7JR\|UxRTBwNEG0OFch\|ryP	NUDzXoNIW0GQR1XS
HOS	NHLab3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{nM[mlEPTB;MD60NVY5OiEQvF2=	MX3TRW5ITVJ?
LN-405	NYXGfVloT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTBwNEG2PFch\|ryP	M2fMOXNCVkeHUh?=
A427	M4nqdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmrYTWM2OD1yLkSxPVgyKM7:TR?=	Mo\0V2FPT0WU
CAL-12T	NEWySXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnpXYpKSzVyPUCuOFI4QCEQvF2=	M3PBXXNCVkeHUh?=
SW756	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHXFVnJKSzVyPUCuOFQyQDNizszN	MkS2V2FPT0WU
YAPC	M37CO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7xW2ZKSzVyPUCuOFUxQCEQvF2=	M3X2NHNCVkeHUh?=
GOTO	NXzKSW1sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkTkTWM2OD1yLkS1NVYh\|ryP	MnHKV2FPT0WU
C3A	MoTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHLIZYdKSzVyPUCuOFU1OzdizszN	NFHTWHVUSU6JRWK=
UM-UC-3	MkXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUHJR\|UxRTBwNEW0O{DPxE1?	NUC3NFFoW0GQR1XS
NCI-H1573	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{nGO2lEPTB;MD60OVU3QSEQvF2=	MWHTRW5ITVJ?
LS-411N	NET3O\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHvZcXNKSzVyPUCuOFY2OjdizszN	NUj5[lV5W0GQR1XS
COR-L23	Ml6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3rhSmlEPTB;MD60Olc3PCEQvF2=	Mn:3V2FPT0WU
HCE-4	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXnGfYdYUUN3ME2wMlQ4PDR4IN88US=>	M{TsPHNCVkeHUh?=
NCI-H2291	MkfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkP2TWM2OD1yLkS3PFk3KM7:TR?=	NEXjSpdUSU6JRWK=
A101D	MkPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnWwTWM2OD1yLkS4NFU{KM7:TR?=	MlzQV2FPT0WU
HT-3	NHP4doVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHTEZ3NKSzVyPUCuOFgzOTdizszN	NX3pbXNUW0GQR1XS
HOP-62	M4iyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGPPVm5KSzVyPUCuOFk5PjVizszN	MV7TRW5ITVJ?
PC-3	NWOzOIc6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIjPW5hKSzVyPUCuOVE2ODdizszN	MnzrV2FPT0WU
CTV-1	NGjMfJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkjxTWM2OD1yLkWyOlY6KM7:TR?=	M3frfHNCVkeHUh?=
PANC-08-13	MnLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{HFO2lEPTB;MD61N\|E4PyEQvF2=	M4LhVHNCVkeHUh?=
CAL-120	NV61cGJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWexbohxUUN3ME2wMlU{Ozl7IN88US=>	MVnTRW5ITVJ?
UMC-11	Ml31S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlraTWM2OD1yLkW1NlM1KM7:TR?=	MWDTRW5ITVJ?
MSTO-211H	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmTMTWM2OD1yLkW1O\|YzKM7:TR?=	MU\TRW5ITVJ?
NCI-H2126	NULaWVNnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEjYV\|ZKSzVyPUCuOVY5OTVizszN	Mn3hV2FPT0WU
SNU-C2B	MmLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37vN2lEPTB;MD61O\|k4PyEQvF2=	MmLDV2FPT0WU
DBTRG-05MG	NWTjSpM{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmrvTWM2OD1yLkW4NFU{KM7:TR?=	NHvHZ3JUSU6JRWK=
MKN1	NWLzWpVyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTBwNUi3PFMh\|ryP	M17pSHNCVkeHUh?=
ES3	NYr6N4h2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTBwNUmxNlQh\|ryP	MlnzV2FPT0WU
OVCAR-3	MofrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3nxXmlEPTB;MD61PVM1OSEQvF2=	MUHTRW5ITVJ?
ACHN	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4D4[2lEPTB;MD62NFU3QSEQvF2=	Ml7sV2FPT0WU
SW872	Mo\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvhdYZzUUN3ME2wMlYxPzZ\|IN88US=>	NH;EOI9USU6JRWK=
CP66-MEL	NUm1PIdQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHRbWJKSzVyPUCuOlA6PjlizszN	MnzXV2FPT0WU
NCI-H661	NHPoNFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoDVTWM2OD1yLk[xNVA1KM7:TR?=	M4ruUnNCVkeHUh?=
UACC-893	NV3MUINRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2L4S2lEPTB;MD62N\|Y5OSEQvF2=	NGXHeVBUSU6JRWK=
JVM-3	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1PNS2lEPTB;MD62N\|gxPCEQvF2=	MmfkV2FPT0WU
SF268	NWDmdVNlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXLJR\|UxRTBwNkSzOFkh\|ryP	NF7k[Y9USU6JRWK=
OCI-AML2	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTBwNkWzPVch\|ryP	NX\mZpl2W0GQR1XS
RPMI-8226	Mk[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUHJR\|UxRTBwNk[zNlMh\|ryP	NYLDfFFMW0GQR1XS
MKN28	NHjHc5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTBwNk[2NlQh\|ryP	NVzQfZFPW0GQR1XS
MDA-MB-453	M{fCPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnznTWM2OD1yLk[3NVgh\|ryP	MUHTRW5ITVJ?
BV-173	MkfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1T6XmlEPTB;MD62PFY4QSEQvF2=	MYTTRW5ITVJ?
NCI-H358	NIjTe4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1zxeWlEPTB;MD62PFczPiEQvF2=	M2fvSXNCVkeHUh?=
NCI-H1651	Mn;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{W3UWlEPTB;MD63JO69VQ>?	NWW1Z3RQW0GQR1XS
MDA-MB-415	MlPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn:zTWM2OD1yLkewPFI6KM7:TR?=	NWjkbJlpW0GQR1XS
8305C	M3vKWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHZT5V4UUN3ME2wMlczPDl6IN88US=>	NEDG[FFUSU6JRWK=
EFM-19	M3;Q[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnX6TWM2OD1yLkezOlcyKM7:TR?=	NUezXYpZW0GQR1XS
RERF-LC-MS	NYTHVW5qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jUZ2lEPTB;MD63OFYyOyEQvF2=	MnnUV2FPT0WU
A388	NXzlOI5HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEm1cXdKSzVyPUCuO\|Y1PjdizszN	NHjudIhUSU6JRWK=
GI-ME-N	M1LOW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnaTWM2OD1yLke3NlM2KM7:TR?=	NHz0OmJUSU6JRWK=
IGR-1	NILiZ2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV7JR\|UxRTBwN{mwOFMh\|ryP	MmThV2FPT0WU
LNCaP-Clone-FGC	NWfHU2tHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlL4TWM2OD1yLkiwNFA1KM7:TR?=	NGG2WYlUSU6JRWK=
SK-MEL-3	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWrtb4VbUUN3ME2wMlgyPTB6IN88US=>	NISyeJZUSU6JRWK=
UACC-257	NUnjbZRET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfwSpNMUUN3ME2wMlgzOjNzIN88US=>	MnHsV2FPT0WU
OE33	Mn\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTBwOEWxNFEh\|ryP	M{nMOXNCVkeHUh?=
QIMR-WIL	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjmdGZKSzVyPUCuPFUyPDFizszN	M17WR3NCVkeHUh?=
NCI-H2009	NXjmUJJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHlfIlKSzVyPUCuPFU{OTFizszN	MYXTRW5ITVJ?
NCI-H522	Mn7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3ZUXVkUUN3ME2wMlg4Pzh\|IN88US=>	NHezWHNUSU6JRWK=
Saos-2	NVG3fldkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTBwOEe4O\|Eh\|ryP	NUPaempkW0GQR1XS
NB17	NHm2WpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTBwOEiwNlUh\|ryP	Mk\5V2FPT0WU
D-392MG	NWOwU3F4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPuSZpvUUN3ME2wMlg6OzV4IN88US=>	MULTRW5ITVJ?
SHP-77	M3rpOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M33MeWlEPTB;MD65NFQ5PSEQvF2=	MXPTRW5ITVJ?
SK-MEL-30	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnXXVlKSzVyPUCuPVEyQDVizszN	MX;TRW5ITVJ?
GCIY	M3Prbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1rRcWlEPTB;MD65NVg1OyEQvF2=	M{TaZXNCVkeHUh?=
HCC70	NUH6XVN2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MojITWM2OD1yLkmyNFU6KM7:TR?=	NIfqW3dUSU6JRWK=
LU-65	NF3vZYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRTBwOUK1PVEh\|ryP	NULS[YdQW0GQR1XS
NCI-H1563	NIHqO2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlTOTWM2OD1yLkm0PFY2KM7:TR?=	MlPFV2FPT0WU
KURAMOCHI	NX;VcVJGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFjmUHZKSzVyPUCuPVUyQTJizszN	MnPWV2FPT0WU
PA-1	M3fhRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWryN\|g6UUN3ME2wMlk2PDJ2IN88US=>	NVvNUZVrW0GQR1XS
NOS-1	M2\PdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTBwOUe0PFkh\|ryP	M3vVTnNCVkeHUh?=
NCI-H69	M2PuWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoXZTWM2OD1yLkm3OlM1KM7:TR?=	MoDmV2FPT0WU
KYSE-450	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVPNVYUxUUN3ME2wMlk5PjJ4IN88US=>	MWrTRW5ITVJ?
8505C	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTBwOUm5PFIh\|ryP	MoDvV2FPT0WU
TGBC24TKB	NHizOppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX\zd3VDUUN3ME2xMlAxODh2IN88US=>	MojRV2FPT0WU
PFSK-1	NE[xZ\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\5fI91UUN3ME2xMlAyPDJ6IN88US=>	MlzRV2FPT0WU
EKVX	M2jEfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVewcnROUUN3ME2xMlA{OTJzIN88US=>	NETk[5RUSU6JRWK=
RCM-1	NH;ITlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTFwMEW1NFch\|ryP	NES2c2dUSU6JRWK=
SW900	NIfwR3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnHLTWM2OD1zLkC3PFMh\|ryP	NI\3cXdUSU6JRWK=
D-542MG	NXrJZYJKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1XUNWlEPTB;MT6wO\|g2PSEQvF2=	NUXRTFFGW0GQR1XS
SK-PN-DW	M3TWeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTFwMUCwOVYh\|ryP	MUPTRW5ITVJ?
NCI-H727	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlzpTWM2OD1zLkGwNVU1KM7:TR?=	M{G5d3NCVkeHUh?=
SW837	NXn5Z4VDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvmXWpKSzVyPUGuNVA6PTRizszN	NX:0UG5DW0GQR1XS
BT-20	NVe3bnZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF33[HJKSzVyPUGuNVEzODRizszN	NUO1XY9XW0GQR1XS
RH-18	MmfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmrmTWM2OD1zLkGzNVA{KM7:TR?=	NI[2RXdUSU6JRWK=
TE-12	M4LscGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3T5XGlEPTB;MT6xN\|M{OyEQvF2=	MYXTRW5ITVJ?
NB10	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHTMe4VKSzVyPUGuNVM{PDRizszN	NH\aflZUSU6JRWK=
AU565	NGPqZmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGrTTG9KSzVyPUGuNVU6PzNizszN	NHK1bJZUSU6JRWK=
OAW-42	NEHWVHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFTRRYZKSzVyPUGuNVg{ODZizszN	M1PGTnNCVkeHUh?=
DJM-1	NG\LRm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIK2U\|FKSzVyPUGuNVk5QDFizszN	NX3GO3UxW0GQR1XS
HH	MnvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUn2TI9WUUN3ME2xMlI{QDNzIN88US=>	NVHTbpdpW0GQR1XS
LAMA-84	NVHsclNkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGTNfnNKSzVyPUGuNlc{QTRizszN	MWXTRW5ITVJ?
KNS-42	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDTZ2o{UUN3ME2xMlMxOjl4IN88US=>	M2rFcHNCVkeHUh?=
NCI-H2052	NUK0NXZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmXzTWM2OD1zLkOwOVA4KM7:TR?=	M1TRTHNCVkeHUh?=
MLMA	MofZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3[zVmlEPTB;MT6zNlQxPyEQvF2=	NU\KelNwW0GQR1XS
NB12	M1SxO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTFwM{W2N\|Yh\|ryP	MUTTRW5ITVJ?
NCI-H1838	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGr2T2FKSzVyPUGuN\|Y{ODZizszN	NHLleZdUSU6JRWK=
NCI-H526	M3LHcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnm3TWM2OD1zLkO3PFU{KM7:TR?=	M2TUfnNCVkeHUh?=
LS-123	NVS4VVJnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTFwM{mwPVQh\|ryP	MlfYV2FPT0WU
HDLM-2	MmqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7UUWt6UUN3ME2xMlM6OjdzIN88US=>	MmTCV2FPT0WU
MC-IXC	NYLpW5c1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVXJR\|UxRTFwNEKzO\|Eh\|ryP	MkfWV2FPT0WU
HCT-15	Mn65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGTMdZdKSzVyPUGuOFMxPjhizszN	NWPHZYdmW0GQR1XS
NCI-H596	NXXiSoxnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{i4NGlEPTB;MT60OVA3OSEQvF2=	NGfsWJBUSU6JRWK=
ZR-75-30	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHXVW4dKSzVyPUGuOFcxQDJizszN	NIPybm5USU6JRWK=
A704	NHXZV3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjuWZFZUUN3ME2xMlY3PTZ\|IN88US=>	MornV2FPT0WU
OVCAR-4	M{LuVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTFwNkm2NFch\|ryP	Ml\PV2FPT0WU
SW1417	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGD6do5KSzVyPUGuO\|I5PDlizszN	NWjxdI9EW0GQR1XS
CAS-1	MnrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH;HNWJKSzVyPUGuO\|M6OzZizszN	MWfTRW5ITVJ?
IST-SL1	M{nDXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1f4ZmlEPTB;MT63PVc2QSEQvF2=	MnexV2FPT0WU
A253	NHLMbm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkTCTWM2OD1zLkiyNlM6KM7:TR?=	NF3W[4xUSU6JRWK=
EW-16	NHnjbmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M121OGlEPTB;MT64Nlg4PSEQvF2=	MmftV2FPT0WU
SK-NEP-1	Ml;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnVe2pxUUN3ME2xMlg3QTh6IN88US=>	MV3TRW5ITVJ?
NCI-H226	NIjIcmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIDDN4hKSzVyPUGuPFk{PTlizszN	NWTvRZNoW0GQR1XS
HOP-92	NHr2dpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEHveHRKSzVyPUGuPVYxQTlizszN	MWfTRW5ITVJ?
NCI-H441	NG[wV2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVP2doxpUUN3ME2yMlAzOzN5IN88US=>	Mk\0V2FPT0WU
LU-139	NVvmOHJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDmTWM2OD1{LkCzNVE1KM7:TR?=	MXnTRW5ITVJ?
SJRH30	M2PSPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknXTWM2OD1{LkC0NlU{KM7:TR?=	MWTTRW5ITVJ?
MG-63	NWfYTnlOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\Hc2tKSzVyPUKuNVQyOTFizszN	MlrEV2FPT0WU
NH-12	NUHaNHBET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPuTWM2OD1{LkG1NFA3KM7:TR?=	MYDTRW5ITVJ?
NB7	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWnXNnVvUUN3ME2yMlE6Pjd\|IN88US=>	M3TTOnNCVkeHUh?=
LB771-HNC	M2rjcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3npS2lEPTB;Mj6yNFU6PSEQvF2=	NUjJO2pZW0GQR1XS
HCC1569	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3LQWGlEPTB;Mj6yOFU5OyEQvF2=	MYDTRW5ITVJ?
D-283MED	M4\heWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXYZ2xjUUN3ME2yMlI1Pzh{IN88US=>	NFXnUYxUSU6JRWK=
J-RT3-T3-5	NHLkTJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlnsTWM2OD1{LkK1N\|UyKM7:TR?=	MkjXV2FPT0WU
ATN-1	NFfsVXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV7JR\|UxRTJwM{OwPFIh\|ryP	MljyV2FPT0WU
HCC1954	NITse3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF\TcnNKSzVyPUKuN\|Q1ODhizszN	NEnJTFRUSU6JRWK=
SCC-15	NYjISVNsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4PvbWlEPTB;Mj6zPVMyOiEQvF2=	M4LzVnNCVkeHUh?=
COLO-668	NHH1SY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVO0Znc2UUN3ME2yMlQ{OiEQvF2=	M1TXd3NCVkeHUh?=
LB373-MEL-D	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfiTWM2OD1{LkW0Olc4KM7:TR?=	M1;B[XNCVkeHUh?=
no-10	NGLMUpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlPFTWM2OD1{LkW0PVQ4KM7:TR?=	MUjTRW5ITVJ?
HT-1197	M3fBdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mkn6TWM2OD1{Lk[zNVg5KM7:TR?=	NVn0VFlwW0GQR1XS
DU-145	M1zpU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml\iTWM2OD1{Lke5NVYzKM7:TR?=	MULTRW5ITVJ?
SK-N-AS	Mo[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUfxPHhQUUN3ME2yMlg1Pjl{IN88US=>	MXLTRW5ITVJ?
MOLT-4	Mnm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnzlTWM2OD1{Lki1N\|IzKM7:TR?=	MnvLV2FPT0WU
EW-22	MmPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDSUpZKSzVyPUKuPVI5PDFizszN	NGT2cVVUSU6JRWK=
DB	MkTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\lS2lEPTB;Mj65O\|c2QSEQvF2=	MV7TRW5ITVJ?
HL-60	NGPEem5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzJSnNKSzVyPUOuNFQ{PzZizszN	MWDTRW5ITVJ?
SK-N-DZ	MlXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlTjTWM2OD1\|LkC1NFc2KM7:TR?=	MX7TRW5ITVJ?
NY	MlrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTNwMEi1OFIh\|ryP	MWfTRW5ITVJ?
T47D	NFfnXYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFTaUW9KSzVyPUOuNVA2PThizszN	MonvV2FPT0WU
NCI-H2029	NFWwSotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjET3ZvUUN3ME2zMlIzPDd5IN88US=>	MY\TRW5ITVJ?
KARPAS-299	NYrHNnVyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rTNGlEPTB;Mz6yOlAzPyEQvF2=	NYrzOnY3W0GQR1XS
KM-H2	M4DzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFTOT5hKSzVyPUOuN\|A3QCEQvF2=	MkXhV2FPT0WU
CHP-134	MkjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLrWW1UUUN3ME2zMlQ4OzlizszN	NU\BRoRrW0GQR1XS
22RV1	Ml3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmH4TWM2OD1\|LkS5NVY5KM7:TR?=	MnrZV2FPT0WU
NB5	NGnLb3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXW4XYlKUUN3ME2zMlUxPjh7IN88US=>	NYnaeIhTW0GQR1XS
CW-2	NY\XS4o2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWTTW5ZkUUN3ME2zMlU2OzF2IN88US=>	NWrIWpRoW0GQR1XS
EFO-21	NVLCOlRST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2f5cmlEPTB;Mz61Olk1KM7:TR?=	MnLqV2FPT0WU
HuH-7	MmqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zFdWlEPTB;Mz61PFQyPCEQvF2=	NV\PcYtXW0GQR1XS
ALL-PO	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1XUXmlEPTB;Mz62NlM{PSEQvF2=	NYrnWGoxW0GQR1XS
EM-2	M1PjOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXzR\|NjUUN3ME2zMlY6ODFzIN88US=>	NIPVU\|BUSU6JRWK=
KLE	NUXKbnp[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkPpTWM2OD1\|LkezNFI6KM7:TR?=	MVzTRW5ITVJ?
NEC8	NUP6cVkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRTNwOUG4NFgh\|ryP	Mnj2V2FPT0WU
KP-N-YN	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\4UVhwUUN3ME2zMlk{PDd4IN88US=>	NHfsSZlUSU6JRWK=
SK-MEL-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo[wTWM2OD12LkCzOVE5KM7:TR?=	NInBR3NUSU6JRWK=
CAL-54	M{WzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWT5W5FDUUN3ME20MlA2QTFizszN	MoDWV2FPT0WU
MS-1	NVnOflNlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmHxTWM2OD12LkG2NVU2KM7:TR?=	MojwV2FPT0WU
NCI-H209	NITVNVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1HaXWlEPTB;ND6yPVk6QSEQvF2=	M2jmPHNCVkeHUh?=
NOMO-1	M{HvSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYPPR4gzUUN3ME20MlMzOTNzIN88US=>	NFv3XppUSU6JRWK=
RPMI-2650	MnrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2j0bWlEPTB;ND6zOlMzPyEQvF2=	MW\TRW5ITVJ?
NCI-H810	M{KyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTRwM{m3N\|Yh\|ryP	NVi0UYxLW0GQR1XS
Ca9-22	Mn\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTRwNEW2PVEh\|ryP	MXrTRW5ITVJ?
ES4	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHXZfY1KSzVyPUSuOFcxQTVizszN	NHf2NZhUSU6JRWK=
ES6	M4TH[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEXzSYpKSzVyPUSuOFk3PTdizszN	NX\VSFFoW0GQR1XS
DMS-114	MmnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1\uXWlEPTB;ND61OFY6OSEQvF2=	M2[4NHNCVkeHUh?=
ONS-76	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX7HSYlRUUN3ME20MlU4QTVizszN	NYP0ZmpLW0GQR1XS
K-562	NV3LfFZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTRwN{O4NVQh\|ryP	MkXqV2FPT0WU
MHH-NB-11	NUniNmRWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVPJR\|UxRTRwN{W0OlEh\|ryP	NFPJXXJUSU6JRWK=
Calu-3	MkH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXLJR\|UxRTRwN{i1OFgh\|ryP	MYHTRW5ITVJ?
HT55	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTRwOES1OFUh\|ryP	MWPTRW5ITVJ?
SK-N-FI	NEi3OItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGrtdlRKSzVyPUSuPFUxODlizszN	NIrTRmJUSU6JRWK=
ES1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkPYTWM2OD12Lki2NFU4KM7:TR?=	NGWze4RUSU6JRWK=
SF126	NUPSVoc5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoO1TWM2OD12LkmzNVg1KM7:TR?=	MX\TRW5ITVJ?
ES5	NH7YNIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHy4T3RKSzVyPUWuNVI1OjdizszN	NYGz[5VoW0GQR1XS
LoVo	NW\SbFBoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;adGlEPTB;NT6xOVg4OSEQvF2=	MVPTRW5ITVJ?
SNU-387	NUHXOnRIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVGyfY96UUN3ME21MlMzOzN7IN88US=>	NXi2b\|NYW0GQR1XS
C8166	NI\JSIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjMSHY3UUN3ME21MlM3OzN7IN88US=>	MUjTRW5ITVJ?
LS-1034	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoSwTWM2OD13LkSyN\|A4KM7:TR?=	MlPvV2FPT0WU
GR-ST	NXnoWXNTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVu3eYx5UUN3ME21MlUzOjBzIN88US=>	MlXmV2FPT0WU
NCI-H1092	NWrRd\|NXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml31TWM2OD13LkeyPFQ{KM7:TR?=	MkL0V2FPT0WU
647-V	Mmq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWSwR\|FHUUN3ME21Mlc1PzB4IN88US=>	MXnTRW5ITVJ?
EW-13	NUTxWmZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\5VodKSzVyPUWuO\|Y3OjdizszN	NXjLTppIW0GQR1XS
KGN	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTZwMEm5NlEh\|ryP	M3X2N3NCVkeHUh?=
D-423MG	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXPJR\|UxRTZwNECyPFQh\|ryP	NU[xb2xUW0GQR1XS
ECC10	M2PH[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1THNWlEPTB;Nz6xNFExOSEQvF2=	MnLiV2FPT0WU
TE-5	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2r0XmlEPTB;Nz60NVI6QCEQvF2=	NYKzSVJVW0GQR1XS
P12-ICHIKAWA	NWfpcJFxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUXLWYNnUUN3ME23MlQ2PTJ\|IN88US=>	MnXkV2FPT0WU
NCI-H82	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWHJR\|UxRTdwNEW3NFEh\|ryP	NFPjVpNUSU6JRWK=
NCI-H1993	M2\6WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV\HPJhvUUN3ME23Mlg{ODZ\|IN88US=>	NUfSXmhjW0GQR1XS
RH-1	NEDCcI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUTHSZpVUUN3ME23Mlg2OjR2IN88US=>	MmLrV2FPT0WU
SW948	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{TI[GlEPTB;Nz65OlA1QSEQvF2=	M{mxSXNCVkeHUh?=
CAL-33	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV:zWnQ{UUN3ME23Mlk6QTN6IN88US=>	NFrVOYdUSU6JRWK=
U-266	MnfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrjcGhKSzVyPUiuNVU4PzdizszN	MWrTRW5ITVJ?
CAL-72	MlroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWfmfXV7UUN3ME24MlIxOzJizszN	MoDBV2FPT0WU
SNU-423	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2rzemlEPTB;OT6zOlY3PiEQvF2=	MoriV2FPT0WU
KG-1	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1TNb2lEPTB;OT61PFQ2PiEQvF2=	M4DHWXNCVkeHUh?=
HCC1395	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1Xn[mlEPTB;OT65NlM2OiEQvF2=	M33pdXNCVkeHUh?=
BE-13	Mo\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYLxUVhvUUN3ME2xNE45QDl{IN88US=>	M2LmNnNCVkeHUh?=
MKN7	M4qyVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jFO2lEPTB;MUCuPVc3PSEQvF2=	MlrrV2FPT0WU
697	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXnJR\|UxRTFzLkG0O\|Ih\|ryP	MXrTRW5ITVJ?
LU-135	NH\aeHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTFzLkKzNFch\|ryP	NVXjSlZyW0GQR1XS
ES7	NH3CZW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{\KfmlEPTB;MUGuN\|MyOyEQvF2=	NXnkWpVPW0GQR1XS
SK-HEP-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4XEOmlEPTB;MUGuO\|Y1PiEQvF2=	M4\je3NCVkeHUh?=
BEN	M{O4R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIiwOZdKSzVyPUGxMlg2OSEQvF2=	NX7oW\|V2W0GQR1XS
NCI-H1770	MkjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF61b\|VKSzVyPUGyMlEzPiEQvF2=	MWjTRW5ITVJ?
SW13	NUC2cHBYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;nWGxKSzVyPUGyMlE2PDFizszN	M1H6UHNCVkeHUh?=
MZ1-PC	MmHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;yTYJKSzVyPUGyMlU1PTJizszN	NIGzR5pUSU6JRWK=
Mo-T	Mmm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX21elFGUUN3ME2xNk44PDJzIN88US=>	M1;0d3NCVkeHUh?=
HLE	M{PzZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGPGW3VKSzVyPUGyMlgzOTVizszN	M4j1fHNCVkeHUh?=
RCC10RGB	Mo\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUDOR3RzUUN3ME2xN{43PzFizszN	NFmzUlJUSU6JRWK=
COLO-320-HSR	MkDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk[xTWM2OD1zMz63N\|gyKM7:TR?=	M2TNN3NCVkeHUh?=
BHT-101	NI\XPZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTF\|LkizOFUh\|ryP	NGHrZWdUSU6JRWK=
OCUB-M	NXHmWmxvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHrO[XFKSzVyPUG0MlE3ODJizszN	NV7pd5JyW0GQR1XS
MEG-01	Ml\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmrlTWM2OD1zND6zO\|A5KM7:TR?=	MY\TRW5ITVJ?
RS4-11	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3zrdWlEPTB;MUSuO\|QzKM7:TR?=	NEfOdlJUSU6JRWK=
MN-60	Mn\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4j6TGlEPTB;MUSuO\|g6PCEQvF2=	NHL2[nNUSU6JRWK=
NCI-H1304	MknpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrDXGNKSzVyPUG1MlA1OjVizszN	NYXCXmEzW0GQR1XS
Ramos-2G6-4C10	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFf0VXJKSzVyPUG1MlA2QDFizszN	MoDVV2FPT0WU
NCI-H2342	NGHQZpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2nUVGlEPTB;MUWuNlA1PCEQvF2=	MX3TRW5ITVJ?
LAN-6	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\pOGlKSzVyPUG1MlQ1OTRizszN	M1S5RXNCVkeHUh?=
JVM-2	NGjH[2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoKzTWM2OD1zNT61O\|Q5KM7:TR?=	M4L2U3NCVkeHUh?=
P30-OHK	MnrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2OyXmlEPTB;MU[uNFYyPCEQvF2=	M3TGVXNCVkeHUh?=
C-33-A	NYXsVIp2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTF4Lk[yNVQh\|ryP	NFHSdHhUSU6JRWK=
RPMI-8866	NE[1XWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFjPXXRKSzVyPUG2Mlg1QTZizszN	MkOwV2FPT0WU
NCI-H630	NEHycYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MonqTWM2OD1zNj64OVM4KM7:TR?=	NYnSU2pFW0GQR1XS
KYSE-140	NXTOSJlGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXTJR\|UxRTF5LkKwNlgh\|ryP	MVPTRW5ITVJ?
T84	MkK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\vTWM2OD1zOD64Olk2KM7:TR?=	M3HWdXNCVkeHUh?=
KU-19-19	NEftXlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PpcGlEPTB;MUiuPVYxQCEQvF2=	NXzpSpA6W0GQR1XS
BALL-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWjWTZBbUUN3ME2xPU4{Ozl7IN88US=>	MU\TRW5ITVJ?
Calu-6	M{fqPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHH2T4dKSzVyPUG5MlQ6OiEQvF2=	MU\TRW5ITVJ?
EGI-1	NW\jWnk6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUD0W3QzUUN3ME2xPU42QThizszN	MlzkV2FPT0WU
MFH-ino	NYLme5o1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGDLd5pKSzVyPUG5Mlc1PTRizszN	M2npZ3NCVkeHUh?=
GB-1	NHnEWHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTJyLkO1N\|Uh\|ryP	NY[2dm91W0GQR1XS
NCI-H1693	MkXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVq0TXU2UUN3ME2yNE43PTB3IN88US=>	M3nyNXNCVkeHUh?=
SW1116	M4LFZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYC5PXRGUUN3ME2yNE46OzZ{IN88US=>	M3TtWnNCVkeHUh?=
H-EMC-SS	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXnTWM2OD1{Mj6wOFUh\|ryP	MYfTRW5ITVJ?
D-502MG	Mor5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;EUHBKSzVyPUKyMlgzPjFizszN	MYnTRW5ITVJ?
IA-LM	M4rYV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2TqdWlEPTB;MkOuNlQ6OyEQvF2=	M1LXbnNCVkeHUh?=
SW1463	NGnzTmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTJ\|Lke5JO69VQ>?	MWTTRW5ITVJ?
JAR	NXm0bGczT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NULHZoxuUUN3ME2yOE4{Ojl\|IN88US=>	NUfGO\|FVW0GQR1XS
HT	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYjHe5ltUUN3ME2yOE41PzV\|IN88US=>	MofMV2FPT0WU
LCLC-103H	NXvL[YRiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzQSFZKSzVyPUK0Mlg1PDlizszN	Mn:5V2FPT0WU
SNU-449	Mnv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTJ2Lki3OFEh\|ryP	MlzzV2FPT0WU
KE-37	NGnTXIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVXlRYxHUUN3ME2yOU4xQTJ6IN88US=>	NXPze2d[W0GQR1XS
NCI-H1623	NGfBfYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGHEN\|RKSzVyPUK3MlE{ODNizszN	NUfHenJJW0GQR1XS
MOLT-13	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTJ5LkO1NVYh\|ryP	NHPqS5FUSU6JRWK=
COLO-741	MoX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVHKUYdWUUN3ME2zNU4{OzN\|IN88US=>	NUPmbphSW0GQR1XS
NB6	NI\Ne\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUX0eZhRUUN3ME2zNk4zQDd4IN88US=>	MYDTRW5ITVJ?
MOLT-16	NUXHSI9rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXPKO\|BTUUN3ME2zN{4xODV3IN88US=>	MUPTRW5ITVJ?
IST-MES1	MnP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTN2LkC1OFEh\|ryP	MUfTRW5ITVJ?
A4-Fuk	M1f6Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NET2WJFKSzVyPUO1MlA3PiEQvF2=	MmTnV2FPT0WU
CAL-85-1	NFXKTmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoO5TWM2OD1\|NT6yPFE4KM7:TR?=	MoTCV2FPT0WU
CCRF-CEM	MlzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NITzfYFKSzVyPUO3MlE2OzZizszN	MkjFV2FPT0WU
HAL-01	MlTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37TPGlEPTB;M{iuOFg5QSEQvF2=	M1nOdXNCVkeHUh?=
HEL	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PkVmlEPTB;NEOuN\|QxQSEQvF2=	NEXrW\|VUSU6JRWK=
EW-1	NGiwNIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3W5U2lEPTB;NEOuOFc3QCEQvF2=	NHnPfoZUSU6JRWK=
MDA-MB-231	M2D6SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MW\JR\|UxRTR3LkGxPVkh\|ryP	MlzEV2FPT0WU
ABC-1	NYjYfGRjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHzUfVlKSzVyPUS2Mlg2OzhizszN	M2qzSnNCVkeHUh?=
NCI-H446	NEPlenZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1Owc2lEPTB;NEiuOVA2QCEQvF2=	NVH4bpc5W0GQR1XS
MHH-PREB-1	NGH0e4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmGwTWM2OD12OT62NFA4KM7:TR?=	NVi1NodtW0GQR1XS
DOHH-2	NFTDS\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NULZV2sxUUN3ME20PU43PjV4IN88US=>	NGDpemNUSU6JRWK=
GCT	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlfETWM2OD12OT62PVc3KM7:TR?=	MWXTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	α-Synuclein / HSP90 / HSP70 / HSP32 / αB-Crystallin; PubMed: 20090920 PLoS One Immunoblot analysis of heat shock protein induction. Cells were treated with 17-AAG (1–200 nM, 24 h), or subjected to heat shock (HS: 44°C, 30 min, 24 h recovery) or to MG-132 (MG: 1 µM, 24 h). Cell lysates were prepared and immunoblot analysis was carried out with antibodies against the individual proteins as indicated on the right. Co, untreated control. EGFR / PDGFR / AKT / MAPK / c-RAS; PubMed: 18682579 Neuro Oncol 17-AAG promotes the degradation of HSP90 client proteins that are involved in the pathology of glioblastoma multiforme (GBM). Glioma cell lines were treated with increasing concentrations of 17-AAG for 48 h, and protein lysates were run on Western blots. HSP90 client proteins known to be involved in gliomagenesis showed degradation while nonclient proteins remained unaffected by 17-AAG treatment. pAKT / pMAPK / pRb; PubMed: 18682579 Neuro Oncol The phosphorylated states of signaling proteins involved in glioma growth are also affected by 17-AAG treatment. Cleaved PARP / Survivin; PubMed: 18827603 J Thorac Oncol Western analysis of expression levels of cleaved PARP and Survivin in MM cell lines. β-Actin served as loading control. LATS1 / p-LATS1 / YAP / CTGF; PubMed: 25712415 J Cell Mol Med Effects of 17-AAG on the expression of LATS1, p-LATS1, YAP and CTGF. The expression levels of YAP and CTGF proteins, indicated by Western blot assay, were down-regulated, while LATS1 was upregulated in a dose-dependent manner in 17-AAG treated groups compared to the untreated group.	20090920 18682579 18827603 25712415
Immunofluorescence	STAT3; PubMed: 27279418 Mol Med Rep Effects of 17-AAG on STAT3 expression of H446 cells. (A) Control group; (B) 3.125 mg/l; (C) 6.25 mg/l. 17-AAG, 17-allylamino-17-demethoxygel-danamycin; STAT3, signal transducer and activator of transcription 3; DAPI, 4′,6-diamidino-2-phenylindole. YAP / TAZ; PubMed: 25290150 PLoS One Reduction in cytoplasmic distribution accompanied by increased nuclear localization of YAP/TAZ was more apparent in cells treated with 45 nM 17-AAG (red channel for YAP/TAZ and blue channel for nucleus). Statistical comparisons were performed using one-way Kruskal-Wallis multiple comparison, ***p<0.001 compared with control (0 nM). β-catenin / E-cadherin; PubMed: 25290150 PLoS One Co-localization of β-catenin (Red) and E-cadherin (Green) was observed at the cell-cell junctions (white arrows) both in siCtrl and siCTGF cells after 17-AAG treatment. Scale bar is 20 µm.	27279418 25290150
Growth inhibition assay	Cell viability; PubMed: 18682579 Neuro Oncol 17-AAG inhibits the growth of human glioma cell lines. Human glioma cell lines and a nontumorigenic fibroblast cell line were treated with increasing concentrations of 17-AAG for 4 days, and the effect on cell growth was assessed by a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay. The 50% inhibitory concentration (IC50) of all glioma cell lines ranged from 0.05 to 0.5 μM 17-AAG, as compared to 1.5 μM for the nontumorigenic cells.	18682579

In vivo

17-AAG displays significantly higher binding affinity for Hsp90 from 3T3-src, B16 or CT26 xenografts in nude mice with IC50 values of 8-35 nM as compared with that from the normal tissues with IC50 values of 200-600 nM. ^[1] Administration of 17-AAG (~50 mg/kg) causes significant decline in AR, HER2, HER3, and Akt expression in a dose-dependent manner with >50% decline at dose of 50 mg/kg, resulting in the dose-dependent inhibition of androgen-dependent (CWR22) and -independent (CWR22R and CWRSA6) prostate cancer xenografts growth by 67%, 80% and 68% at dose of 50 mg/kg, respectively. ^[2]

Protocol

Kinase Assay:^[1]	+ Expand Hsp90 binding assays: Purified native Hsp90 protein or cell lysates from HER-2-overexpressing cancer cells (BT474, N87, SKOV3 and SKBR3) or BT474 breast carcinoma cells in lysis buffer (20 mM HEPES, pH 7.3, 1 mM EDTA, 5 mM MgCl₂, 100 mM KCl) are incubated with various concentrations of 17-AAG for 30 minutes at 4 °C, and then incubated with biotin-GM linked to BioMag streptavidin magnetic beads for 1 hour at 4 °C. Tubes are placed on a magnetic rack, and the unbound supernatant removed. The magnetic beads are washed three times in lysis buffer and heated for 5 minutes at 95 °C in SDS–PAGE sample buffer. Samples are analysed on SDS protein gels, and western blots done using indicated antibodies. Bands in the western blots are quantified using the Bio-rad Fluor-S MultiImager, and the percentage inhibition of binding of Hsp90 to the biotin-GM is calculated. The IC50 reported is the concentration of 17-AAG needed to cause half-maximal inhibition of binding.
Cell Research:^[1]	+ Expand Cell lines: BT474, SKBR3, N87, SKOV3, MCF7, MDA468, Hs578T, Hs578Bst, A549, HT29, U87, SKMG3, HT1080, RPTEC, NDF, HMVEC, HMEC, HUVEC, and PBMC cells Concentrations: Dissolved in DMSO, final concentrations ~10 μM Incubation Time: 5 days Method: Cells are seeded in 96-well plates at 2,000 cells per well in a final culture volume of 100 μL for 24 hours before the addition of increasing concentrations of 17-AAG that is incubated for 5 days. Viable cell number is determined using the Celltiter 96 AQueous Nonradioactive Cell Proliferation Assay. The value of the background absorbance at 490 nm (A₄₉₀) of wells not containing cells is subtracted. Percentage of viable cells = (A₄₉₀ of 17-AAG treated sample/A₄₉₀ untreated cells) × 100. The IC50 is defined as the concentration that gave rise to 50% viable cell number. (Only for Reference)
Animal Research:^[2]	+ Expand Animal Models: Male nu/nu athymic mice inoculated s.c. with androgen-dependent CWR22 xenograft, and female nu/nu athymic mice inoculated s.c. with androgen-independent xenografts CWR22R and CWRSA6 Formulation: Dissolved in DMSO, and diluted in egg phospholipids (EPL) vehicle Dosages: ~50 mg/kg Administration: Injection i.p. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	100 mg/mL (170.73 mM)
	Ethanol	5 mg/mL (8.53 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5%DMSO+corn oil For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Tanespimycin (17-AAG) SDF

Molecular Weight	585.69
Formula	C₃₁H₄₃N₃O₈
CAS No.	75747-14-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	CP127374,NSC-330507, KOS 953

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00103272	Terminated	Drug: tanespimycin\|Drug: bortezomib	Adult Acute Basophilic Leukemia\|Adult Acute Eosinophilic Leukemia\|Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Anaplastic Large Cell Lymphoma\|Angioimmunoblastic T-cell Lymphoma\|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue\|Nodal Marginal Zone B-cell Lymphoma\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Acute Myeloid Leukemia\|Recurrent Adult Diffuse Large Cell Lymphoma\|Recurrent Adult T-cell Leukemia/Lymphoma\|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma\|Recurrent Grade 1 Follicular Lymphoma\|Recurrent Grade 2 Follicular Lymphoma\|Recurrent Grade 3 Follicular Lymphoma\|Recurrent Mantle Cell Lymphoma\|Recurrent Marginal Zone Lymphoma\|Recurrent Mycosis Fungoides/Sezary Syndrome\|Recurrent Small Lymphocytic Lymphoma\|Refractory Chronic Lymphocytic Leukemia\|Small Intestine Lymphoma\|Splenic Marginal Zone Lymphoma\|Waldenström Macroglobulinemia	National Cancer Institute (NCI)	April 2005	Phase 1
NCT00098488	Terminated	Drug: tanespimycin\|Biological: rituximab	B-cell Chronic Lymphocytic Leukemia\|Prolymphocytic Leukemia\|Refractory Chronic Lymphocytic Leukemia	National Cancer Institute (NCI)	April 2005	Phase 1
NCT00118248	Completed	Drug: tanespimycin	Recurrent Thyroid Cancer\|Stage IV Follicular Thyroid Cancer\|Stage IV Papillary Thyroid Cancer\|Thyroid Gland Medullary Carcinoma	National Cancer Institute (NCI)	December 2004	Phase 2
NCT00098423	Completed	Drug: tanespimycin\|Drug: cytarabine	Accelerated Phase Chronic Myelogenous Leukemia\|Adult Acute Basophilic Leukemia\|Adult Acute Eosinophilic Leukemia\|Adult Acute Megakaryoblastic Leukemia (M7)\|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)\|Adult Acute Monoblastic Leukemia (M5a)\|Adult Acute Monocytic Leukemia (M5b)\|Adult Acute Myeloblastic Leukemia With Maturation (M2)\|Adult Acute Myeloblastic Leukemia Without Maturation (M1)\|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities\|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)\|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)\|Adult Acute Myelomonocytic Leukemia (M4)\|Adult Erythroleukemia (M6a)\|Adult Pure Erythroid Leukemia (M6b)\|Blastic Phase Chronic Myelogenous Leukemia\|Chronic Myelomonocytic Leukemia\|de Novo Myelodysplastic Syndromes\|Previously Treated Myelodysplastic Syndromes\|Recurrent Adult Acute Lymphoblastic Leukemia\|Recurrent Adult Acute Myeloid Leukemia\|Refractory Anemia With Excess Blasts in Transformation\|Relapsing Chronic Myelogenous Leukemia\|Secondary Acute Myeloid Leukemia\|Secondary Myelodysplastic Syndromes	National Cancer Institute (NCI)	November 2004	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What kind of subtypes does this compound inhibit? HSP90α or HSP90β ?
Answer:
17-AAG can inhibit both HSP90α and HSP90β, but it is unclear how much are they affected respectively. You should note that Hsp90 derived from tumor cells has a 100-fold higher binding affinity for 17-AAG than that from normal cells according to this paper. http://www.nature.com.ezp-prod1.hul.harvard.edu/nature/journal/v425/n6956/full/nature01913.html

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Selective HSP90 Inhibitor

NVP-BEP800 : HSP90β-selective, IC50=58 nM.
Most Potent HSP90 Inhibitor

KW-2478 : HSP90, IC50=3.8 nM.
HSP90 Inhibitor in Clinical Trial

17-DMAG (Alvespimycin) HCl : Phase II for Kidney Cancer.
Newest HSP90 Inhibitor

XL888 : ATP-competitive inhibitor of HSP90 with IC50 of 24 nM.

Related HSP (e.g. HSP90) Products

PU-H71 ^New

PU-H71 is a potent and selective inhibitor of HSP90 with IC50 of 51 nM. Phase 1.
KNK437 ^New

KNK437 is a pan-HSP inhibitor, which inhibits the synthesis of inducible HSPs, including HSP105, HSP72, and HSP40.
VER155008 ^New

VER-155008 is a potent Hsp70 family inhibitor with IC50 of 0.5 μM, 2.6 μM, and 2.6 μM in cell-free assays for HSP70, HSC70, and GRP78, respectively, >100-fold selectivity over HSP90.
Luminespib (AUY-922, NVP-AUY922)

Luminespib (AUY-922, NVP-AUY922) is a highly potent HSP90 inhibitor for HSP90α/β with IC50 of 13 nM /21 nM in cell-free assays, weaker potency against the HSP90 family members GRP94 and TRAP-1, exhibits the tightest binding of any small-molecule HSP90 ligand. Phase 2.
Ganetespib (STA-9090)

Ganetespib (STA-9090) is an HSP90 inhibitor with IC50 of 4 nM in OSA 8 cells, induces apoptosis of OSA cells while normal osteoblasts are not affected; active metabolite of STA-1474. Phase 3.
Alvespimycin (17-DMAG) HCl

Alvespimycin (17-DMAG) HCl is a potent HSP90 inhibitor with IC50 of 62 nM in a cell-free assay. Phase 2.

Features:A synthetic derivative Geldanamycin, with lower hepatotoxicity than parent antibiotic & higher potency and bioavailability than the similar derivative 17-AAG.
Geldanamycin

Geldanamycin is a natural existing HSP90 inhibitor with K_d of 1.2 μM, specifically disrupts glucocorticoid receptor (GR)/HSP association.
HSP990 (NVP-HSP990)

NVP-HSP990 (HSP990) is a novel, potent and selective HSP90 inhibitor for HSP90α/β with IC50 of 0.6 nM/0.8 nM.

Features:NVP-HSP990 is an orally available HSP90 inhibitor and is structurally distinct from other clinical HSP90 inhibitors.
Elesclomol (STA-4783)

Elesclomol (STA-4783) is a novel potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells. Phase 3.
Onalespib (AT13387)

Onalespib (AT13387) is a selective potent Hsp90 inhibitor with IC50 of 18 nM in A375 cells, displays a long duration of anti-tumor activity. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Tanespimycin (17-AAG)

Cited by 35 Publications

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Tanespimycin (17-AAG) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

Tech Support

Frequently Asked Questions

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products

Choose Your Country or Region

By Signaling Pathways

By product type

Tanespimycin (17-AAG)

Cited by 35 Publications

Purity & Quality Control

Choose Selective HSP (e.g. HSP90) Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Tanespimycin (17-AAG) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

Tech Support

Frequently Asked Questions

HSP (e.g. HSP90) Signaling Pathway Map

HSP (e.g. HSP90) Inhibitors with Unique Features

Related HSP (e.g. HSP90) Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)